Adjunctive Atypical Antipsychotics in Major Depressive Disorder: A Network Meta-Analysis Perspective and Consensus Panel Discussion

Objective

The goal of this consensus panel was to generate expert perspectives on the comparative efficacy, safety, tolerability, and clinical relevance of FDA-approved adjunctive atypical antipsychotics for adults with major depressive disorder (MDD) and inadequate response to antidepressant therapy.